Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Lutetium-177 PNT2002 for Prostate Cancer | Open Medscience
PNT2002 / POINT Biopharma, Lantheus
ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following ...
Frontiers | Initial clinical experience with [177Lu]Lu-PNT2002 ...
ASCO 2021: Study Evaluating Metastatic Castrate Resistant Prostate ...
New therapy delays progression of recurrent prostate cancer | UCLA Health
Prostate Cancer Molecular Imaging, Therapy: MIRROR and 177Lu-PNT2002 ...
PSMA-Targeting Radioligand Therapy in Prostate Cancer | Published in ...
Study on Treating Metastatic Castration-Resistant Prostate Cancer with ...
[Lu-177]-PNT2002 for Prostate Cancer Clinical Trial 2023 | Power
177Lu-PNT2002 Significantly Improves rPFS Vs ARPI in Metastatic ...
ESMO 2022: Efficacy and Safety of 177Lu-PNT2002 Prostate-Specific ...
(PDF) Initial clinical experience with [Lu]Lu-PNT2002 radioligand ...
Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate ...
SPLASH: 177Lu-PNT2002 achieves phase 3 outcomes for mCRPC | Urology Times
FDA Fast Tracks 177Lu-PNT2002 for the Treatment of mCRPC | Targeted ...
177Lu-PNT2002 Received FDA Fast Track Designation for Metastatic CRPC
FDA Fast Tracks 177Lu-PNT2002 for the Treatment of mCRPC
Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide ...
177Lu–Prostate-specific Membrane Antigen Radioligand Therapy in ...
1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane ...
Dose‐adapted stereotactic body radiation therapy based on the response ...
ESMO 22: Results of the 177Lu-PNT2002 SPLASH Trial | GU Oncology Now
SPLASH: 177Lu-PNT2002 achieves phase 3 outcomes for mCRPC
Emerging PSMA Radioligand Therapy Shows Benefits for Metastatic ...
ESMO 2025: 177Lutetium-PSMA Therapy Neoadjuvant to Stereotactic ...
Navigating Therapeutic Choices in Prostate Cancer: Effective Decision ...
ESMO 2024: Scientific Congress Highlights: Genitourinary Tumors, Prostate
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation ...
ESMO 2024 Quick Take Insights: Prostate Cancer - #ARANOTE: Darolutamide ...
177Lu-PNT2002 Meets Primary Endpoint in Phase III mCRPC Trial ...
A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [177Lu ...
slide16
🚀 LUNAR phase II trial RCT of pts w/ oligorecurent hormone-sensitive # ...
PSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis ...
ASTRO 2025: 177Lu-PSMA Neoadjuvant to Ablative Radiotherapy for ...
slide15
ESMO 2024 Quick Take Insights: Prostate Cancer
Optimized Therapeutic 177Lu-Labeled PSMA-Targeted Ligands with Improved ...
Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA ...
Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA ...
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company on ...
Chemical structures of selected prostate-targeting radionuclide therapy ...
Frontiers | 177Lu-labeled PSMA targeting therapeutic with optimized ...
AUA 2024: mCRPC: Key Updates in Radioligand Therapy, PSMA Sensitive Disease
The contemporary management of prostate cancer - Chakrabarti - CA: A ...
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant ...
The efficacy benefits of radioisotopes in metastatic castration ...
Systemic Therapy in Patients With Metastatic Castration-Resistant ...
Lilly Plans to Purchase POINT Biopharma, Enhancing Cancer Treatment ...
:%0A%0A[Lu-177]-PNT2002%20for%20Prostate%20Cancer.png?md=1)
